
Finerenone extends kidney protection to non-diabetic CKD, early FIND-CKD data show
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, continues to show kidney and cardiovascular benefits in chronic kidney disease, with FIND-CKD data indicating protection even in patients without diabetes; however, there is a modest rise in serum potassium (about 0.12 mmol/L) and hyperkalemia events occurred in 17% of treated patients versus 13.3% in placebo, overall suggesting good safety and tolerability.













